Lavender oil preparation Silexan is effective in mild-to-moderate major depression : a randomized, placebo- and reference-controlled trial
© 2024. The Author(s)..
Anxiety and depressive disorders have overlapping symptoms and share common neurobiological pathways. Antidepressant drugs have been demonstrated to be efficacious in anxiety as well. Vice versa, it may also be promising to investigate the efficacy of anxiolytic drugs such as silexan in major depressive disorder (MDD). Patients with a mild or moderate, single or recurrent episode of MDD and a total score of 19-34 points on the Montgomery Åsberg Depression Rating Scale (MADRS) were randomized to receive 1 × 80 mg/d silexan, 1 × 50 mg/d sertraline, or placebo double-blind, double-dummy for 56 days. The primary outcome measure was the MADRS total score change between baseline and treatment end. Treatment groups were compared using a treatment policy estimand. 498 subjects (silexan 170, sertraline 171, placebo 157) were treated and analyzed. After 8 weeks, silexan and sertraline were superior to placebo for MADRS total score reduction, with absolute differences to placebo of 2.17 (95% confidence interval: 0.58; 3.76) points and 2.59 (1.02; 4.17) points, respectively (p < 0.01). Moreover, silexan was superior to placebo for alleviation of functional impairment according to the Sheehan Disability Scale with a difference of 2.40 (1.04; 3.76) points (p < 0.001). Both treatments were well tolerated; eructation was the most frequent adverse effect of silexan. The study confirms the antidepressant efficacy of silexan in mild or moderate MDD, including significant improvements in the subjects' functional capacity. The results for sertraline confirm the assay sensitivity of the trial. Both drugs were well tolerated.Trial registrationEudraCT2020-000688-22 first entered on 12/08/2020.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
European archives of psychiatry and clinical neuroscience - (2024) vom: 01. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kasper, Siegfried [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical trial |
|---|
| Anmerkungen: |
Date Revised 01.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s00406-024-01783-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370476468 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370476468 | ||
| 003 | DE-627 | ||
| 005 | 20240403000952.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240403s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00406-024-01783-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1361.xml |
| 035 | |a (DE-627)NLM370476468 | ||
| 035 | |a (NLM)38558147 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kasper, Siegfried |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lavender oil preparation Silexan is effective in mild-to-moderate major depression |b a randomized, placebo- and reference-controlled trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Anxiety and depressive disorders have overlapping symptoms and share common neurobiological pathways. Antidepressant drugs have been demonstrated to be efficacious in anxiety as well. Vice versa, it may also be promising to investigate the efficacy of anxiolytic drugs such as silexan in major depressive disorder (MDD). Patients with a mild or moderate, single or recurrent episode of MDD and a total score of 19-34 points on the Montgomery Åsberg Depression Rating Scale (MADRS) were randomized to receive 1 × 80 mg/d silexan, 1 × 50 mg/d sertraline, or placebo double-blind, double-dummy for 56 days. The primary outcome measure was the MADRS total score change between baseline and treatment end. Treatment groups were compared using a treatment policy estimand. 498 subjects (silexan 170, sertraline 171, placebo 157) were treated and analyzed. After 8 weeks, silexan and sertraline were superior to placebo for MADRS total score reduction, with absolute differences to placebo of 2.17 (95% confidence interval: 0.58; 3.76) points and 2.59 (1.02; 4.17) points, respectively (p < 0.01). Moreover, silexan was superior to placebo for alleviation of functional impairment according to the Sheehan Disability Scale with a difference of 2.40 (1.04; 3.76) points (p < 0.001). Both treatments were well tolerated; eructation was the most frequent adverse effect of silexan. The study confirms the antidepressant efficacy of silexan in mild or moderate MDD, including significant improvements in the subjects' functional capacity. The results for sertraline confirm the assay sensitivity of the trial. Both drugs were well tolerated.Trial registrationEudraCT2020-000688-22 first entered on 12/08/2020 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Clinical trial | |
| 650 | 4 | |a Depression | |
| 650 | 4 | |a Lavender | |
| 650 | 4 | |a Silexan | |
| 650 | 4 | |a Treatment efficacy | |
| 700 | 1 | |a Volz, Hans-Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Möller, Hans-Jürgen |e verfasserin |4 aut | |
| 700 | 1 | |a Schläfke, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Klement, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Anghelescu, Ion-George |e verfasserin |4 aut | |
| 700 | 1 | |a Seifritz, Erich |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European archives of psychiatry and clinical neuroscience |d 1996 |g (2024) vom: 01. Apr. |w (DE-627)NLM012966681 |x 1433-8491 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:01 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00406-024-01783-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 01 |c 04 | ||